Daiwa Securities Group’s ImmunityBio IBRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$757K Sell
86,500
-112,700
-57% -$853K ﹤0.01% 888
2026
Q1
$1.53M Buy
199,200
+196,027
+6,178% +$1.34M ﹤0.01% 704
2025
Q4
$6K Hold
3,173
﹤0.01% 1219
2025
Q3
$8K Hold
3,173
﹤0.01% 1169
2025
Q2
$8K Buy
3,173
+553
+21% +$1.49K ﹤0.01% 1126
2025
Q1
$8K Hold
2,620
﹤0.01% 1105
2024
Q4
$7K Hold
2,620
﹤0.01% 1146
2024
Q3
$10K Hold
2,620
﹤0.01% 1131
2024
Q2
$17K Sell
2,620
-110
-4% -$725 ﹤0.01% 1138
2024
Q1
$15K Hold
2,730
﹤0.01% 1146
2023
Q4
$14K Buy
2,730
+1,120
+70% +$3.51K ﹤0.01% 1148
2023
Q3
$3K Hold
1,610
﹤0.01% 1198
2023
Q2
$4K Hold
1,610
﹤0.01% 1197
2023
Q1
$3K Hold
1,610
﹤0.01% 1187
2022
Q4
$8K Buy
1,610
+127
+9% +$697 ﹤0.01% 1124
2022
Q3
$7K Sell
1,483
-24,106
-94% -$110K ﹤0.01% 1144
2022
Q2
$95K Buy
25,589
+3,157
+14% +$12.7K ﹤0.01% 1029
2022
Q1
$126K Buy
22,432
+6,676
+42% +$41K ﹤0.01% 1015
2021
Q4
$96K Buy
15,756
+9,936
+171% +$74.7K ﹤0.01% 1013
2021
Q3
$57K Buy
5,820
+5,074
+680% +$55.8K ﹤0.01% 1040
2021
Q2
$11K Buy
746
+530
+245% +$8.76K ﹤0.01% 1043
2021
Q1
$5K Buy
216
+12
+6% +$311 ﹤0.01% 1075
2020
Q4
$3K Buy
+204
New +$1.96K ﹤0.01% 1084
2018
Q4
Sell
-439
Closed -$2K 1161
2018
Q3
$2K Hold
439
﹤0.01% 1128
2018
Q2
$1K Hold
439
﹤0.01% 1165
2018
Q1
$2K Buy
+439
New +$1.93K ﹤0.01% 1125

Other funds holding IBRX

Daiwa Securities Group's IBRX Position: Q2 2026 in Review

Daiwa Securities Group reduced its ImmunityBio (IBRX) stake by 57% in Q2 2026, selling an estimated $853K and leaving 86,500 shares worth $757K. The position accounts for ﹤0.01% of the portfolio, ranked #888.

Daiwa Securities Group first reported a position in IBRX in Q1 2018 and has held it in 26 quarters since. The position peaked at $1.53M in Q1 2026. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Daiwa Securities Group held 86,500 shares of ImmunityBio worth $757K as of Q2 2026.
  • Daiwa Securities Group sold 112,700 ImmunityBio shares in Q2 2026, an estimated $853K.
  • ImmunityBio made up ﹤0.01% of Daiwa Securities Group's portfolio in Q2 2026, its #888 holding.
  • Daiwa Securities Group first reported a position in ImmunityBio in Q1 2018 and has held it in 26 quarters since.
  • Daiwa Securities Group's ImmunityBio position peaked at $1.53M in Q1 2026.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Daiwa Securities Group's 13F filing for Q2 2026, filed 31 Jul 2026.